Developer docs
API playgroundTry for free, no card

Search company profiles

Cellanome

Full company profile

uuid0000a99

Namestring
Cellanome
Legal namestring
Cellanome, Inc.
Websiteurl
cellanome.com
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Cellanome is a private biotechnology company founded in 2020 that has developed the R3200 Platform, an integrated live-cell analysis system combining proprietary CellCage™ photopatterning, automated fluorescent and brightfield imaging, and single-cell transcriptomics into a single workflow. The platform is designed to address a fragmentation problem in cell biology, where traditional tools force researchers to choose between observing live-cell behavior and capturing molecular state. CellCage™ enclosures—biocompatible hydrogel microenvironments formed via digital micromirror device photopatterning in 2-3 seconds per image—keep cells viable, attached, and trackable for days to weeks, supporting 5,000+ parallel enclosures per lane. The Perturb-LINK methodology enables phenotype-first pooled CRISPR screening where live-cell function is measured directly before being linked to guide identity, transcriptome, morphology, and surface protein readouts.

The platform is delivered through the R3200 instrument (with onboard GPU and liquid handling robotics), proprietary flow cells pre-coated with extracellular matrix proteins and barcoded capture probes, the Cellanome Cloud software for visualization and analysis, and a suite of assays and workflows. The company sells to academic research institutions and biopharmaceutical companies via direct enterprise field sales, offering both instrument purchase and full-service CRISPR screening options. Cellanome is headquartered in Foster City, California, with additional offices in San Diego and Singapore, and has raised over $200 million from investors including 8VC, DFJ Growth, Premji Invest, and Wing Venture Capital.

Named customers and collaborators span UCSF (Matt Spitzer, Olaia Vila, and Camilla Valente labs), the Salk Institute (Joe Ecker and James Walker labs), and the Mayo Clinic (Annarita Scaramozza lab), with applications in tumor-immune interaction studies, neurobiology, aging and senescence, and immuno-oncology. Leadership includes CEO Omead Ostadan, CSO Gary Schroth, Co-founder Mostafa Ronaghi, Chairman Jay Flatley (former Illumina CEO), and board member Rowan Chapman. Revenue is not publicly disclosed, and pricing is quote-based for both platform purchase and service engagements.

Short descriptiontext

Cellanome is a private biotech that sells the R3200 Platform—an integrated system combining proprietary CellCage™ hydrogel enclosures, live-cell imaging, and single-cell transcriptomics—to academic labs and biopharmaceutical companies for multimodal cell analysis across immunology, oncology, neurobiology, and aging research.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersFoster City, United States
HQ citystring
Foster City
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
single-cell analysis, live-cell imaging, CRISPR screening, multi-omics platform, cell biology instruments
Industry2 codes
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Analytical Laboratory Instrument Manufacturing334516
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Surgical & Medical Instruments & Apparatus3841
Product category
Single-Cell Analysis Instruments
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1R3200 Platform Hardware Sales
TypeHardware Sales
Description

Sale of the R3200 instrument system - an integrated platform combining instrumentation, flow cells, and software. Customers can purchase the platform and run workflows in their own labs.

cellanome.com
2Flow Cells and Consumables
TypeHardware Sales
Description

Proprietary flow cells with CellCage™ technology and consumables for running experiments on the R3200 platform.

cellanome.com
3CRISPR Screening Services
TypeProfessional Services
Description

Cellanome-run service lab can run CRISPR screens end-to-end for customers. Optional deeper analysis packages available for ranking perturbations and connecting phenotypic hits to transcriptomic programs.

cellanome.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
Pricing details1 tier
1Platform purchase or service model
ModelOtherBilling cadenceMulti-year contract
Notes

Cellanome offers both platform purchase (for customers to run in their own labs) and service lab options (Cellanome runs the screen end-to-end). Pricing not publicly disclosed.

cellanome.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1CellCage
Description

Proprietary technology enabling customizable, biocompatible enclosures for single cells that support living cells in controlled microenvironments for culture, perturbation, and measurement of cell-cell interactions.

cellanome.com
+3 more records
Core offering1 text field

Cellanome develops and sells the R3200 Platform, an integrated live-cell analysis system that combines proprietary CellCage hydrogel microenvironments, automated fluorescent live-cell imaging, and single-cell transcriptomics. The platform enables researchers to track cellular behavior, morphology, and gene expression from the same individual cells over time. The company also operates a service lab that runs CRISPR screening experiments end-to-end for customers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Platform generates 5,000+ individual enclosures per lane, each generating independent time-lapse imaging and transcriptomic data
+1 more record
Product overview1 text field

Cellanome offers the R3200 Platform as its core unified product, which integrates four main components: the R3200 Instrument, Flow Cells, Assays & Workflows, and the Cellanome Cloud Platform. At the foundation of the platform is CellCage Technology—biocompatible, programmable hydrogel micro-environments that create custom enclosures around individual cells or small ensembles. This technology enables long-term live-cell culture, time-lapse imaging, perturbation, and single-cell transcriptomics all within the same experimental workflow. The platform is designed for applications across immunology, oncology, neuroscience, and aging research, supporting both phenotype-first CRISPR screening and multimodal single-cell analysis.

Product and service6 records
1R3200 Platform
CategoryLife sciences instrument platform
Description

Cellanome's flagship integrated live-cell analysis system combining instrumentation, flow cells, assays, and cloud software. Tracks live cells over time via time-lapse imaging while maintaining them in CellCage enclosures, then recovers single-cell transcriptomes from the same cells, linking behavioral history to molecular state.

2CellCage Technology
CategoryProprietary consumable/technology component
Description

Foundational proprietary technology consisting of biocompatible, light-guided hydrogel microenvironments that form customizable enclosures around selected cells. Preserves native morphology and supports culturing, time-lapse imaging, perturbation, and sequencing within a unified workflow.

3Cellanome Cloud Platform
CategoryCloud software
Description

Cloud-based software component of the R3200 Platform providing experiment planning, time-course image visualization, and results linking across experimental timepoints.

4Flow Cells
CategoryProprietary consumables
Description

Programmable flow cells that serve as the foundation for CellCage enclosure formation. Pre-coated with fibronectin, PLO-laminin, or other extracellular matrix proteins to support adherent cell attachment and growth, with barcoded capture probes for transcriptomic profiling.

5Assays & Workflows
CategoryAssay kits and workflows
Description

Pre-configured experimental workflows and assay capabilities including morphology analysis, secretion profiling, transcriptomics, cell-cell interaction studies, CRISPR screening, and time-resolved functional readouts supporting both endpoint and longitudinal designs.

6CRISPR Screening Services
CategoryService offering
Description

Cellanome-run service lab that runs CRISPR screens end-to-end for customers, with optional deeper analysis packages available for ranking perturbations and connecting phenotypic hits to transcriptomic programs.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Early collaborator during platform development. Lab uses Cellanome R3200 for cell-extrinsic CRISPR screening to study tumor-induced immune dysfunction. Dr. Spitzer describes collaboration as 'never had such a productive and close-knit collaborative interaction with a new technology company.'

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multiple research collaborations including Joe Ecker Lab (multimodal single-cell analysis) and James Walker Lab (protoplast physiology and transcriptomics). Researchers present findings at conferences using Cellanome platform.

Strategic tierSecondaryTypeStrategic or Co-development Partner
Description

Collaboration with Mayo Clinic staff scientist Dr. Annarita Scaramozza on identifying subsets of senescent cells using platform capabilities for multi-modal analysis.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

10x Genomics is the dominant single-cell analysis platform company (Chromium, Visium, Xenium). Cellanome directly competes by offering a complementary multimodal live-cell + transcriptomics workflow where 10x primarily provides endpoint single-cell assays. Both target academic and biopharma research customers.

TypeDirect peer
Description

Berkeley Lights (acquired by Bruker) developed the Beacon platform for live-cell functional screening and analysis using optoelectronic chips. Most directly comparable to Cellanome in combining live-cell imaging with downstream molecular readouts, though Cellanome's CellCage hydrogel approach is technologically distinct.

TypeDirect peer
Description

Standard BioTools offers mass cytometry and microfluidic single-cell analysis instruments (Hyperion, CyTOF, Biomark). Competes with Cellanome in serving immunology and cell biology researchers needing high-dimensional single-cell data, though with different underlying technology platforms.

TypeEmerging player
Description

Mission Bio provides single-cell multi-omics for genomics and proteomics (Tapestri platform). An emerging player with partial overlap to Cellanome's single-cell transcriptomics and CRISPR screening capabilities, but focused more on DNA/genomics rather than live-cell phenotyping.

TypeEmerging player
Description

Parse Biosciences offers scalable single-cell RNA sequencing (Evercode). Competes in the single-cell transcriptomics space with Cellanome but at a different price point and scale, without live-cell imaging or functional screening capabilities.

TypeBroad incumbent
Description

Sartorius is a major bioprocessing and cell analysis tools provider serving pharma and academic customers with a broad portfolio including cell line development and live-cell analysis. Overlaps with Cellanome in cell biology applications but as a much broader incumbent rather than a focused specialist.

TypeBroad incumbent
Description

BD Biosciences is a major life science tools provider with flow cytometry, cell sorting, and single-cell analysis instruments (FACSDiscover, BD CellView). Overlaps with Cellanome in immunology and cell biology research, but as a broad incumbent with much larger scale.

8Takara Bio
TypeEmerging player
Description

Takara Bio offers single-cell genomics solutions (SMART-seq, ICELL8) and molecular biology reagents. Competes with Cellanome in single-cell transcriptomics reagent and instrument markets, particularly in academic research settings.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellanome

Single-Cell Analysis Instrumentscellanome.com

Cellanome is a private biotech that sells the R3200 Platform—an integrated system combining proprietary CellCage™ hydrogel enclosures, live-cell imaging, and single-cell transcriptomics—to academic labs and biopharmaceutical companies for multimodal cell analysis across immunology, oncology, neurobiology, and aging research.

What Cellanome does

Cellanome is a private biotechnology company founded in 2020 that has developed the R3200 Platform, an integrated live-cell analysis system combining proprietary CellCage™ photopatterning, automated fluorescent and brightfield imaging, and single-cell transcriptomics into a single workflow. The platform is designed to address a fragmentation problem in cell biology, where traditional tools force researchers to choose between observing live-cell behavior and capturing molecular state. CellCage™ enclosures—biocompatible hydrogel microenvironments formed via digital micromirror device photopatterning in 2-3 seconds per image—keep cells viable, attached, and trackable for days to weeks, supporting 5,000+ parallel enclosures per lane. The Perturb-LINK methodology enables phenotype-first pooled CRISPR screening where live-cell function is measured directly before being linked to guide identity, transcriptome, morphology, and surface protein readouts.

The platform is delivered through the R3200 instrument (with onboard GPU and liquid handling robotics), proprietary flow cells pre-coated with extracellular matrix proteins and barcoded capture probes, the Cellanome Cloud software for visualization and analysis, and a suite of assays and workflows. The company sells to academic research institutions and biopharmaceutical companies via direct enterprise field sales, offering both instrument purchase and full-service CRISPR screening options. Cellanome is headquartered in Foster City, California, with additional offices in San Diego and Singapore, and has raised over $200 million from investors including 8VC, DFJ Growth, Premji Invest, and Wing Venture Capital.

Named customers and collaborators span UCSF (Matt Spitzer, Olaia Vila, and Camilla Valente labs), the Salk Institute (Joe Ecker and James Walker labs), and the Mayo Clinic (Annarita Scaramozza lab), with applications in tumor-immune interaction studies, neurobiology, aging and senescence, and immuno-oncology. Leadership includes CEO Omead Ostadan, CSO Gary Schroth, Co-founder Mostafa Ronaghi, Chairman Jay Flatley (former Illumina CEO), and board member Rowan Chapman. Revenue is not publicly disclosed, and pricing is quote-based for both platform purchase and service engagements.

Cellanome firmographics

Firmographics
Name
Cellanome
Legal name
Cellanome, Inc.
Website
https://cellanome.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
101–250 employees
Short description
Cellanome is a private biotech that sells the R3200 Platform—an integrated system combining proprietary CellCage™ hydrogel enclosures, live-cell imaging, and single-cell transcriptomics—to academic labs and biopharmaceutical companies for multimodal cell analysis across immunology, oncology, neurobiology, and aging research.
Ownership category
akta.pro rank

Cellanome industry classification

Industry
Product category
Single-Cell Analysis Instruments
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Analytical Laboratory Instrument Manufacturing (334516)
SIC
Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAIAD
Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAJ
In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Single-cell analysis
  • Live-cell imaging
  • CRISPR screening
  • Multi-omics platform
  • Cell biology instruments

Where Cellanome is headquartered

Location

Headquarters

HQ city
Foster City
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Cellanome business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. R3200 Platform Hardware Sales: Sale of the R3200 instrument system - an integrated platform combining instrumentation, flow cells, and software. Customers can purchase the platform and run workflows in their own labs.
  2. Flow Cells and Consumables: Proprietary flow cells with CellCage™ technology and consumables for running experiments on the R3200 platform.
  3. CRISPR Screening Services: Cellanome-run service lab can run CRISPR screens end-to-end for customers. Optional deeper analysis packages available for ranking perturbations and connecting phenotypic hits to transcriptomic programs.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractPlatform purchase or service model

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Cellanome product offering

Product offering

Core offering

Cellanome develops and sells the R3200 Platform, an integrated live-cell analysis system that combines proprietary CellCage hydrogel microenvironments, automated fluorescent live-cell imaging, and single-cell transcriptomics. The platform enables researchers to track cellular behavior, morphology, and gene expression from the same individual cells over time. The company also operates a service lab that runs CRISPR screening experiments end-to-end for customers.

Product overview

Cellanome offers the R3200 Platform as its core unified product, which integrates four main components: the R3200 Instrument, Flow Cells, Assays & Workflows, and the Cellanome Cloud Platform. At the foundation of the platform is CellCage Technology—biocompatible, programmable hydrogel micro-environments that create custom enclosures around individual cells or small ensembles. This technology enables long-term live-cell culture, time-lapse imaging, perturbation, and single-cell transcriptomics all within the same experimental workflow. The platform is designed for applications across immunology, oncology, neuroscience, and aging research, supporting both phenotype-first CRISPR screening and multimodal single-cell analysis.

Differentiator

Problem solved

Functional benefit

Brands

  • CellCage: Proprietary technology enabling customizable, biocompatible enclosures for single cells that support living cells in controlled microenvironments for culture, perturbation, and measurement of cell-cell interactions.
  • CellCage Enclosures (CCEs)
  • R3200 Platform
  • Perturb-LINK

Products and services

  • R3200 Platform Cellanome's flagship integrated live-cell analysis system combining instrumentation, flow cells, assays, and cloud software. Tracks live cells over time via time-lapse imaging while maintaining them in CellCage enclosures, then recovers single-cell transcriptomes from the same cells, linking behavioral history to molecular state.
  • CellCage Technology Foundational proprietary technology consisting of biocompatible, light-guided hydrogel microenvironments that form customizable enclosures around selected cells. Preserves native morphology and supports culturing, time-lapse imaging, perturbation, and sequencing within a unified workflow.
  • Cellanome Cloud Platform Cloud-based software component of the R3200 Platform providing experiment planning, time-course image visualization, and results linking across experimental timepoints.
  • Flow Cells Programmable flow cells that serve as the foundation for CellCage enclosure formation. Pre-coated with fibronectin, PLO-laminin, or other extracellular matrix proteins to support adherent cell attachment and growth, with barcoded capture probes for transcriptomic profiling.
  • Assays & Workflows Pre-configured experimental workflows and assay capabilities including morphology analysis, secretion profiling, transcriptomics, cell-cell interaction studies, CRISPR screening, and time-resolved functional readouts supporting both endpoint and longitudinal designs.
  • CRISPR Screening Services Cellanome-run service lab that runs CRISPR screens end-to-end for customers, with optional deeper analysis packages available for ranking perturbations and connecting phenotypic hits to transcriptomic programs.

Quantifiable outcome

  • Platform generates 5,000+ individual enclosures per lane, each generating independent time-lapse imaging and transcriptomic data
  • +1 more outcomes

Companies that use Cellanome

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles2 records

Cellanome technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Cellanome partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core and secondary.

  • UCSF (Dr. Matt Spitzer Lab)coreStrategic or Co-development PartnerEarly collaborator during platform development. Lab uses Cellanome R3200 for cell-extrinsic CRISPR screening to study tumor-induced immune dysfunction. Dr. Spitzer describes collaboration as 'never had such a productive and close-knit collaborative interaction with a new technology company.'
  • Salk Institute for Biological StudiescoreStrategic or Co-development PartnerMultiple research collaborations including Joe Ecker Lab (multimodal single-cell analysis) and James Walker Lab (protoplast physiology and transcriptomics). Researchers present findings at conferences using Cellanome platform.
  • Mayo ClinicsecondaryStrategic or Co-development PartnerCollaboration with Mayo Clinic staff scientist Dr. Annarita Scaramozza on identifying subsets of senescent cells using platform capabilities for multi-modal analysis.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Cellanome competitors and assessment

Company assessment

Direct peers

  • 10x Genomics: 10x Genomics is the dominant single-cell analysis platform company (Chromium, Visium, Xenium). Cellanome directly competes by offering a complementary multimodal live-cell + transcriptomics workflow where 10x primarily provides endpoint single-cell assays. Both target academic and biopharma research customers.
  • Bruker Cellular Analysis (formerly Berkeley Lights): Berkeley Lights (acquired by Bruker) developed the Beacon platform for live-cell functional screening and analysis using optoelectronic chips. Most directly comparable to Cellanome in combining live-cell imaging with downstream molecular readouts, though Cellanome's CellCage hydrogel approach is technologically distinct.
  • Standard BioTools (formerly Fluidigm): Standard BioTools offers mass cytometry and microfluidic single-cell analysis instruments (Hyperion, CyTOF, Biomark). Competes with Cellanome in serving immunology and cell biology researchers needing high-dimensional single-cell data, though with different underlying technology platforms.

Emerging players

  • Mission Bio: Mission Bio provides single-cell multi-omics for genomics and proteomics (Tapestri platform). An emerging player with partial overlap to Cellanome's single-cell transcriptomics and CRISPR screening capabilities, but focused more on DNA/genomics rather than live-cell phenotyping.
  • Parse Biosciences: Parse Biosciences offers scalable single-cell RNA sequencing (Evercode). Competes in the single-cell transcriptomics space with Cellanome but at a different price point and scale, without live-cell imaging or functional screening capabilities.
  • Takara Bio: Takara Bio offers single-cell genomics solutions (SMART-seq, ICELL8) and molecular biology reagents. Competes with Cellanome in single-cell transcriptomics reagent and instrument markets, particularly in academic research settings.

Broad incumbents

  • Sartorius: Sartorius is a major bioprocessing and cell analysis tools provider serving pharma and academic customers with a broad portfolio including cell line development and live-cell analysis. Overlaps with Cellanome in cell biology applications but as a much broader incumbent rather than a focused specialist.
  • Becton Dickinson (BD Biosciences): BD Biosciences is a major life science tools provider with flow cytometry, cell sorting, and single-cell analysis instruments (FACSDiscover, BD CellView). Overlaps with Cellanome in immunology and cell biology research, but as a broad incumbent with much larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellanome social profiles

Digital presence

Cellanome financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellanome leadership team

Management profile

Number of profiles

Profiles9 records

Cellanome funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellanome M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellanome

What does Cellanome do?

Cellanome develops and sells the R3200 Platform, an integrated live-cell analysis system that combines proprietary CellCage hydrogel microenvironments, automated fluorescent live-cell imaging, and single-cell transcriptomics. The platform enables researchers to track cellular behavior, morphology, and gene expression from the same individual cells over time. The company also operates a service lab that runs CRISPR screening experiments end-to-end for customers.

Is Cellanome a public or private company?

Cellanome is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellanome founded?

Cellanome was founded in 2020. It employs 101 to 250 people.

Where is Cellanome based?

Cellanome is headquartered in Foster City, United States, in the North America region.

How does Cellanome make money?

Three revenue lines are on record. R3200 Platform Hardware Sales are the primary driver. The others are flow Cells and Consumables and CRISPR Screening Services.

Who are Cellanome's main competitors?

Direct peers on record are 10x Genomics, Bruker Cellular Analysis (formerly Berkeley Lights) and Standard BioTools (formerly Fluidigm). Emerging players are Mission Bio, Parse Biosciences and Takara Bio. Broad incumbents are Sartorius and Becton Dickinson (BD Biosciences).

Does Cellanome have an API?

No public API is recorded for Cellanome.

What industry is Cellanome in?

Cellanome's product category is Single-Cell Analysis Instruments. Its primary akta.pro industry code is HLAAAIAD, Synthetic Biology & Genetic Circuit Design Platforms (pathway engineering, chassis development), with a secondary code of HLAAAIAJ, In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
StartupSeekerCellanome - Funding: $200M+Cellanome, a biotech startup based in Redwood City, United States, has raised over $200 million in funding to develop an automated multi-omics platform for high-throughput live cell phenotypic and functional assays. The platform enables researchers to observe individual cell behaviors and interactions across various stimuli at a granular level, addressing cellular heterogeneity without requiring multiple platforms or additional samples. Founded in 2020, the company employs 14 people and operates in the cell biology research space.General CatalystThe Future of Life Sciences InvestmentGeneral Catalyst outlines its investment strategy in the life sciences sector, focusing on computationally-enabled drug discovery and companies harnessing biological machinery to address global competitive pressures. The firm highlights significant medical advances driven by venture-backed innovation while noting a funding gap in federal research that private capital aims to fill. This strategic overview emphasizes partnerships with emerging biotech firms like Kekulai, Maxion Therapeutics, and Cellanome to drive efficiency and patient outcomes.PremjiinvestCellanome - The Hitchhiker's Guide to Cellular BiologyPremji Invest has partnered with Cellanome to support the development of its new single-cell analysis platform, which enables live-cell functional assays combined with multiomic profiling. This technology allows researchers to observe cellular behavior over time and link phenotypic function with molecular identity, addressing limitations of traditional static assays.LinkedInCellanome's platform for studying live cells without disruptionCellanome has introduced a high-throughput platform that enables the longitudinal study of live cells, such as neurons and senescent cells, without enzymatic dissociation or physical perturbation. The technology utilizes CellCage Enclosures to maintain cells in their natural adherent state, allowing for multi-modal transcriptomic analysis while preserving functional networks.CellanomeReveal Cellular Choreography, See Biology in Motion.Cellanome is a biotechnology company that has developed a live-cell analysis platform integrating time-lapse imaging with single-cell molecular profiling. The technology utilizes proprietary CellCage™ microenvironments to enable researchers to monitor cell behavior and interactions in real-time while preserving cells for downstream transcriptomic assays.CellanomeSingle Cell Research PlatformCellanome has introduced the R3200, a single-cell research platform designed to model complex cell-cell interactions within immune ensembles for immunology research. The system enables scientists to co-culture diverse cells, apply perturbations, and link longitudinal functional dynamics to RNA programs at scale. This technology aims to accelerate mechanistic discoveries and therapeutic development by resolving ambiguities inherent in fragmented measurement workflows.CellanomeTumor Research PlatformCellanome is promoting its R3200 platform and CellCage technology as tools for modeling tumor-immune interactions to improve cancer research and drug discovery. The article highlights case studies demonstrating the platform's ability to track longitudinal dynamics and link cellular responses to RNA programs, such as identifying T-cell priming pathways and characterizing CAR-T cytotoxicity subsets.CellanomeLive Cell Imaging PlatformCellanome has introduced the R3200, an integrated live-cell imaging platform designed to capture multimodal data from single cells or defined ensembles without disrupting their continuity. The system combines automated instrument hardware, programmable flow cells with CellCage enclosures, and a cloud-based analysis pipeline to enable longitudinal studies of cell behavior and interactions. This solution aims to provide high-resolution, temporal context for drug discovery and disease research by linking morphological, functional, and genomic readouts.CellanomeNeural Cell Analysis PlatformCellanome is promoting its neural cell analysis platform, which enables the simultaneous tracking of live neural cell interactions and transcriptomic profiling within preserved 3D structures. The technology allows researchers to link functional outcomes, such as neurite outgrowth or phagocytosis, to specific gene expression programs without disrupting cell morphology. This approach supports disease modeling, drug development screening, and AI training by providing high-fidelity, longitudinal data on neurological processes.CellanomeLive Cell Isolation PlatformCellanome Technology has introduced the CellCage R3200, a live cell isolation platform that utilizes micro-3D printing and AI to create customizable enclosures for extended single-cell culture and transcriptomic profiling. The system enables researchers to track cellular dynamics and interactions over time while linking phenotypic observations directly to molecular data. This technology is being utilized by institutions such as the Salk Institute, Weill Cornell Medicine, and internal Cellanome teams to advance research in oncology, immunology, and neuroscience.